Discovery of XD14, a potent BET bromodomain inhibitor

Xavier Lucas,¹ Daniel Wohlwend,² Martin Hügle,² Manfred Jung,¹ Oliver Einsle,² and Stefan Günther¹


¹Institute of Pharmaceutical Sciences and ²Institute of Biochemistry, Albert-Ludwigs-Universität, Freiburg, Germany xavier.lucas@pharmazie.uni-freiburg.de

Bromodomains are epigenetic mark 'readers' that specifically recognize ε -*N*-acetylated lysine residues. Their potential as therapeutic targets has attracted much attention due to their implication as regulators of disease-relevant gene expression. BET is the most studied bromodomain subfamily so far, and it has been characterized as a key determinant in several types of cancer, particularly leukemia [1,2]. We have performed a structure-based virtual screening and identified 4-acyl pyrroles as a novel class of bromodomain inhibitors [3].


Library preparation

Discovery of XD14

Millions of compounds for screening were collected and processed using the cheminformatics platform **ChemicalToolBoX** [4]. That in-house library is an appealing compilation of small molecules for structure- and ligand-based drug discovery:




We performed a structure-based drug discovery campaign and identified the potent BET bromodomain inhibitor XD14, which features a novel 4acyl pyrrole core. The molecule shows potent and selective antiproliferative activity against leukemia cell lines and no acute toxicity [3]:






Robustness of the model

Molecular models (turquoise) accurately predicthe crystallographic binding mode (pale ted yellow) for some identified hits:



Shifting selectivity towards CREBBP and EP300

We have used the 4-acyl pyrrole scaffold to rationally design compounds with **improved affinity** towards CREBBP and EP300 compared to XD14:






other bromodomains!

201P 202P 203P 205P 207P 209P 210P 211S **Rationally designed compounds**

Conclusions

Structure-based virtual screening is presented as a valid approach in epigenetics. Here, a new class of potent BET bromodomain inhibitors based on 4-acyl pyrroles is described, that mimics the interaction with the natural substrate. The binding mode of XD14, as lead molecule of the new class, could be precisely predicted using *in silico* methods. Rational design allows for the modulation of XD46 to target other therapeutically relevant human bromodomains beyond the BET subfamily.



[1] Prinjha RK et al., "Place your BETs: the therapeutic potential of bromodomains", Trends Pharmacol. Sci., 2012, 33(3): 146-53.

- [2] Lucas X and Günther S, "Targeting the BET family for the treatment of leukemia", Epigenomics (in press).
- [3] Lucas X, Wohlwend D et al., "4-acyl pyrroles: mimicking acetylated lysines in histone code reading", Angew. Chem. Int. Ed. Engl., 2013, 52(52):14055-9.

[4] ChemicalToolBoX website: http://132.230.56.143:8080.